Document text
Principal Investigator: Tejal A. Desai
Organization: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Fiscal Year: 2021
Award: $828,473
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY:
The COVID-19 pandemic, caused by the new coronavirus SARS-CoV-2, has had a remarkable impact on
public health worldwide with the largest number of cases and deaths reported in the United States. Improved
understanding of COVID-19 will accelerate the development of effective therapeutics, which are necessary to
fight SARS-CoV-2 including its new variants. The SARS-CoV-2 human receptor ACE2 is central to disease
pathogenesis and potential therapies. This proposal focuses on the imaging and therapy of SARS-CoV-2 using
a newly developed, ACE2-targeted PET radiotracer and S-protein neutralizing therapies. These therapies
include PLGA nanoparticles bearing recombinant ACE2 (rACE2) and a monoclonal antibody (mAb) 5A6
recently developed at UCSF. Although the techniques and therapies proposed are directly applicable to SARS-
CoV-2, they will also potentially apply to future coronavirus infections and other diseases driven by ACE2
suppression especially acute respiratory distress syndrome (ARDS). Therapies derived from ACE2 itself also
have high impact in the context of SARS-CoV-2 variants that evade vaccines and mAb-based drugs.
We recently identified a cyclic, [68Ga]-NOTA modified ACE2 inhibitory peptide ([68Ga]-NOTA-ACE2pep) as a
PET radiotracer to study SARS-CoV-2 infection and its treatment in vivo. This radiotracer was developed with
the goal of understanding the timing and location of ACE2 suppression in COVID-19, critical in treating infected
patients and identifying disease in the lungs, heart, kidneys, gastrointestinal tract and central nervous system.
ACE2-specific PET imaging will also help us understand the effects of rACE2/mAb therapies, whose
development has lagged behind vaccine rollout. In this proposal, we will first optimize a radiosynthesis of an
analogous 18F-labelled tracer namely [18F]AlF-NOTA-ACE2pep and validate its performance in vitro (Specific
Aim 1). In Specific Aim 2, we use [18F]AlF-NOTA-ACE2pep to image ACE2 loss in transgenic mice and a
COVID-19 murine model. Finally, in Specific Aim 3 we will develop nanoparticle-derived methods to deliver
rACE2/ 5A6 and demonstrate suppression of SARS-CoV-2 infection, when therapy is administered around the
time of exposure. This treatment effect will be shown in vivo using [18F]AlF-NOTA-ACE2pep. Our 3-year R01
proposal prioritizes methods and approaches that can be developed very quickly, in an effort to impact the
COVID-19 pandemic as soon as possible.
The principal investigators of this proposal are Drs. David M. Wilson, Robert Flavell, and Tejal Desai (UCSF)
and Sanjay Jain (Johns Hopkins); as leaders in the field of infection imaging Drs. Wilson and Jain have worked
extensively together. Key infrastructure is already in place at UCSF and Johns Hopkins for the fight against
COVID-19. Specifically, Dr. Jain's BSL3 facility at Johns Hopkins is one of the few places in the world where
the proposed PET-CT studies of SARS-CoV-2 infected animals can be performed. We will therefore harness
the strengths of multiple productive laboratories at UCSF and Johns Hopkins to accomplish the proposed work.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><ACE2><ARDS><Active Sites><Acute Respiratory Distress><Acute Respiratory Distress Syndrome><Adult ARDS><Adult RDS><Adult Respiratory Distress Syndrome><Alimentary Canal><Angiotensin Converting Enzyme><Angiotensin I-Converting Enzyme><Angiotensin Receptor><Animals><Assay><BSL-3 facility><BSL3 facility><Bioassay><Biochemical><Biocompatible Materials><Biodistribution><Biologic Assays><Biological Assay><Biomaterials><CD143 Antigens><CNS Nervous System><COVID><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 therapy><COVID-19 treatment><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 public health crisis><COVID19 therapy><COVID19 treatment><COVID19 virus><CV-19><CV19><Carboxycathepsin><Carboxypeptidase A><Cell Communication and Signaling><Cell Signaling><Central Nervous System><Cessation of life><Chemistry><Clinical Treatment Moab><CoV disease><CoV emergence><CoV-2><CoV2><Coronaviridae Infections><Coronavirus Infections><Cryo-electron Microscopy><Cryoelectron Microscopy><Cyclicity><Da Nang Lung><Death><Development><Digestive Tract><Dipeptidyl Peptidase A><Disease><Disorder><Dose><Drugs><Electron Cryomicroscopy><Enzyme Gene><Enzymes><Exposure to><Fluorides><Future><GI Tract><Gastrointestinal Tract><Gastrointestinal tract structure><Genetic Engineering><Genetic Engineering Biotechnology><Genetic Engineering Molecular Biology><Goals><Heart><Heterogeneity><Human><Image><In Vitro><Infection><Infrastructure><Intracellular Communication and Signaling><Intravenous><Kidney><Kidney Urinary System><Kininase A><Kininase II><Knock-out><Knockout><Label><Laboratories><Lead><Location><Lung><Lung Respiratory System><Mediating><Medication><Methods><Mice><Mice Mammals><Modern Man><Monoclonal Antibodies><Monoclonal Antibody Therapy><Murine><Mus><Neuraxis><Organ><PET><PET Scan><PET imaging><PETSCAN><PETT><Pathogenesis><Patients><Pb element><Peptides><Peptidyl-Dipeptidase A><Performance><Periodicity><Pharmaceutic Preparations><Pharmaceutical Preparations><Physiologic><Physiological><Positron Emission Tomography Medical Imaging><Positron Emission Tomography Scan><Positron-Emission Tomography><Principal Investigator><Proteins><Public Health><Publications><Publishing><Rad.-PET><Radioactive Isotopes><Radioisotopes><Radionuclides><Radiopharmaceutical Compound><Radiopharmaceuticals><Recombinant DNA Technology><Recombinants><Reporting><Resistance><Resolution><Rhythmicity><Route><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 exposure><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 exposure><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scientific Publication><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 exposure><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Shock Lung><Signal Transduction><Signal Transduction Systems><Signaling><Specificity><Stiff lung><Structure><Techniques><Technology><Time><Tracer><Transgenic Mice><United States><Vaccines><Validation><Variant><Variation><Viral><Viral Diseases><Viral Receptor><Virus><Virus Diseases><Virus Receptors><Work><Wuhan coronavirus><alimentary tract><angiotensin converting enzyme 2><angiotensin converting enzyme II><base><biological material><biological signal transduction><biosafety level 3 facility><chelation><cohort><corona virus disease><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus emergence><coronavirus disease><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus emergence><cryo-EM><cryoEM><deploy vaccines><developmental><digestive canal><distribute vaccines><dosimetry><drug/agent><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><exposure to SARS-CoV-2><exposure to SARS-CoV2><exposure to Severe acute respiratory syndrome coronavirus 2><fight against><fighting><genetically engineered><hCoV19><heavy metal Pb><heavy metal lead><imaging><imaging probe><improved><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infection rate><inhibitor><inhibitor/antagonist><injury to organs><mAb therapy><mAbs><mortality><mouse model><murine model><nCoV><nCoV2><nano particle><nano-sized particle><nanoparticle><nanosized particle><new CoV><new corona virus><new coronavirus><novel CoV><novel corona virus><novel coronavirus><organ injury><positron emission tomographic (PET) imaging><positron emission tomographic imaging><positron emitting tomography><preservation><protective effect><pulmonary><radioactive drugs><radiolabel><radiotherapeutic drugs><radiotracer><rate of infection><renal><resistant><response><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe acute respiratory syndrome-CoV><spatiotemporal><therapeutically effective><tool><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><treatment effect><vaccine antibodies><vaccine deployment><vaccine distribution><vaccine induced antibodies><vaccine roll-out><vaccine rollout><vaccine-induced antibodies><viral infection><virus infection><virus-induced disease><wet lung>